Eqis Capital Management, Inc. Biomarin Pharmaceutical Inc Transaction History
Eqis Capital Management, Inc.
- $1.17 Billion
- Q2 2024
A detailed history of Eqis Capital Management, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 5,188 shares of BMRN stock, worth $360,617. This represents 0.04% of its overall portfolio holdings.
Number of Shares
5,188
Previous 4,549
14.05%
Holding current value
$360,617
Previous $397,000
7.56%
% of portfolio
0.04%
Previous 0.03%
Shares
28 transactions
Others Institutions Holding BMRN
# of Institutions
632Shares Held
185MCall Options Held
1.63MPut Options Held
1.2M-
Black Rock Inc. New York, NY22.7MShares$1.58 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.32 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA18.8MShares$1.31 Billion1.14% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$968 Million0.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA9.69MShares$674 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.9B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...